We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+35.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$376M
AUM Growth
+$68.7M
Cap. Flow
+$6.54M
Cap. Flow %
1.74%
Top 10 Hldgs %
62.6%
Holding
53
New
13
Increased
11
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$10.8M
2
ARVN icon
Arvinas
ARVN
+$6.16M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$5.33M
4
CDXS icon
Codexis
CDXS
+$4.14M
5
TGTX icon
TG Therapeutics
TGTX
+$3.78M

Top Sells

Rank Stock Value
1
MOR
MorphoSys AG American Depositary Shares
MOR
+$7.82M
2
BHVN icon
Biohaven
BHVN
+$7.43M
3
TELA icon
TELA Bio
TELA
+$6M
4
GERN icon
Geron
GERN
+$4.06M
5
KALV
KalVista Pharmaceuticals
KALV
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Miscellaneous 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XERS icon
51
Xeris Biopharma Holdings
XERS
$1.57B
– –
-390,000
Closed -$725K
TCON
52
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-238,225
Closed -$848K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2023 Portfolio in Review

As of Q4 2023, Opaleye Management held 53 positions worth $376M, up 22% from $307M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opaleye Management's Q4 2023 filing shows 13 new, 11 increased, 14 reduced and 8 closed positions. Its largest new stake was Ventyx Biosciences: 1,140,000 shares worth $2.82M. The largest sale was MorphoSys AG American Depositary Shares, an estimated $7.82M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q4 2023 buy was Ventyx Biosciences: 1,140,000 shares worth $2.82M.
  • Opaleye Management added most to Codexis in Q4 2023, an estimated $4.14M increase.
  • Opaleye Management's biggest Q4 2023 reduction was MorphoSys AG American Depositary Shares, cutting an estimated $7.82M.
  • Opaleye Management fully exited TELA Bio in Q4 2023, selling an estimated $6M.
  • Opaleye Management's ten largest holdings make up 63% of its $376M portfolio in Q4 2023.
  • Opaleye Management opened 13 new positions and closed 8 in Q4 2023.
  • Opaleye Management's portfolio value rose 22% quarter-over-quarter to $376M.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.